title: [The Carpentier-Edwards porcine valve in the supra annular aortic position. Results after 12 years in a series of 1108 patients].
abstract: In the decision concerning the choice of valvular prosthesis, certain prostheses are considered to be standards of reference: this is the case of the Carpentier-Edwards Supra Annular 2650 porcine bioprosthesis. This study reports the results in a series of patients followed up for 12 years. Between 1983 and 1995, 1108 patients were implanted with this prosthesis for isolated aortic valve replacement. The majority of patients was elderly (mean 78.3 +/- 8.3 years). The follow-up rate was 94%, representing a total of 3 925 patient-years (average 4 +/- 3 years). The survival at 5, 10 and 12 years, operative mortality included, was 70.7%, 46% and 28%. Thromboembolic events to dehiscence represented the commonest complication (0.7% per patient-year). Structural valve degeneration (21 cases) (0.5% per patient-year) was a low risk complication up to 10 years but increased suddenly at the 11th year: age and gender were risk factors for this complication. The actuarial complication-free rate was 94% at 10 years and 82% at 12 years. Other complications were much less common (infectious endocarditis, haemorrage). The Carpentier-Edwards Supra Annular porcine bioprosthesis is associated with a low risk of complications after 10 years' follow-up, especially of valve degeneration. It remains a competitive choice in the register of valve prostheses. As with the other bioprostheses, the main indications are observed in elderly patients.
authors.affiliation: Clinique chirurgicale cardiovasculaire et thoracique, Faculté de médecine de Rennes, hôpital Pontchaillou, CHU de Rennes.
authors.forename: Y
authors.initials: Y
authors.lastname: Logeais
authors.forename: A
authors.initials: A
authors.lastname: Leguerrier
authors.forename: C
authors.initials: C
authors.lastname: Rioux
authors.forename: J
authors.initials: J
authors.lastname: Chaperon
authors.forename: B
authors.initials: B
authors.lastname: Lelong
authors.forename: T
authors.initials: T
authors.lastname: Langanay
authors.forename: J F
authors.initials: JF
authors.lastname: Delambre
authors.forename: A
authors.initials: A
authors.lastname: el Issa
authors.forename: J
authors.initials: J
authors.lastname: Valla
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve; D001705:Bioprosthesis / Q000009:adverse effects / Q000401:mortality; D004696:Endocarditis / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000401:mortality; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012086:Reoperation; D012307:Risk Factors; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology